The Role of a Colon-in-Continuity in Short Bowel Syndrome
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,56 MB, PDF-dokument
Short bowel syndrome (SBS) is a rare gastrointestinal condition that is defined as having less than 200 cm of remaining small intestine. SBS results from extensive surgical resection and is associated with a high risk for intestinal failure (IF) with a need for parenteral support (PS). Depending on the region of intestinal resection, three different main anatomy types can be distinguished from each other. In this review, we synthesize the current knowledge on the role of the colon in the setting of SBS-IF with a colon-in-continuity (SBS-IF-CiC), e.g., by enhancing the degree of intestinal adaptation, energy salvage, and the role of the microbiota. In addition, the effect of the disease-modifying treatment with glucagon-like peptide-2 (GLP-2) analogs in SBS-IF-CiC and how it differs from patients without a colon will be discussed. Overall, the findings explained in this review highlight the importance of preservation of the colon in SBS-IF.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 628 |
| Tidsskrift | Nutrients |
| Vol/bind | 15 |
| Udgave nummer | 3 |
| Antal sider | 13 |
| ISSN | 2072-6643 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
T.V. is supported by the Flanders Research Foundation (FWO Vlaanderen) through a senior clinical research mandate (1830517N).
Funding Information:
P.B.J. has received grants/research support/honoraria or consultation fees from Albumedix A/S, ArTara Therapeutics, Bainan Biotech, Baxter, Coloplast, Ferring, Fresenius Kabi, GLyPharma, Naia Pharma, NPS Pharmaceuticals, Shire, Takeda, The Novo Nordisk Foundation, Therachon, VectivBio and Zealand Pharma. F.J. has received grants/research support/honoraria or consultation fees from Baxter, Fresenius Kabi, Nestlé Health Sciences, BBraun, Theradial, Mayoli, Biocodex, mobile3e Consulting, Carembouche, NPS Pharmaceuticals, Shire, Takeda, Therachon, VectivBio and Zealand Pharma. T.V. has served on the speaker bureau for Fresenius Kabi, Remedus, Takeda, and VectivBio. T.V. has provided clinical advice to Baxter, Shire, Takeda, VectivBio, Zealand Pharma. T.V. has received research grants from Takeda and VectivBio.
Publisher Copyright:
© 2023 by the authors.
ID: 367837289